Related Experiment Video
Updated: May 14, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Preclinical evaluation of statins as a treatment for ovarian cancer
Elizabeth Robinson1, Mandrita Nandi, Laurelle L Wilkinson
1Institute for Science and Technology in Medicine, Guy Hilton Research Centre, Keele University, Thornburrow Drive, Stoke-on-Trent ST4 7QB, UK. a.richardson1@keele.ac.uk
Objective:
To evaluate the potential for statins to treat ovarian cancer.
Methods:
The sensitivity of 7 ovarian cancer cell lines to either statins or statins combined with either carboplatin or paclitaxel was assessed using monolayer cultures. Sensitivity to simvastatin was also evaluated in ovarian cancer spheroids. The kinetics of cell death induced by simvastatin was evaluated by measuring Trypan Blue exclusion. Autophagy induced by simvastatin was assessed by measuring LC3-II, p62 or Rab7 by immunoblotting or immunocytochemistry.
Results:
All statins except pravastatin demonstrated single agent activity against monolayers (IC50=1-35 μM) and spheroids (IC50=1-13 μM). This was mediated by HMG-CoAR inhibition, because either mevalonate or geranylgeraniol prevented the cytotoxic effects of simvastatin. Continuous exposure for 4 days was necessary to cause cell death. Simvastatin caused accumulation of p62 but loss of Rab7, suggesting inhibition of autophagosome trafficking. Accumulation of LC3-II was also observed, even in the presence of bafilomycin, suggesting additional stimulation of an earlier step in autophagy. Knockdown of the key autophagy regulator Atg5 caused a modest increase in the sensitivity of Ovcar-8 cells to simvastatin. Finally, additive or mild antagonist effects were observed when simvastatin was combined simultaneously with either carboplatin or paclitaxel, but when cells were exposed to simvastatin prior to carboplatin, profound antagonism was observed.
Conclusions:
These observations suggest that clinical trials of statins in ovarian cancer should evaluate high doses and schedules that ensure continual inhibition of HMG-CoAR. Simvastatin has conflicting effects on the autophagy pathway and this may contribute to its cytotoxic activity.
Insights
Statins show potential in treating ovarian cancer by inhibiting HMG-CoAR, leading to cell death. Further research should explore high doses and specific schedules for clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Ovarian cancer remains a significant health challenge with limited treatment options.
- Statins, commonly used for cholesterol management, have emerged as potential anti-cancer agents.
Purpose of the Study:
- To investigate the efficacy of statins as a monotherapy and in combination with chemotherapy for ovarian cancer treatment.
- To elucidate the mechanisms underlying statin-induced cytotoxicity, including effects on autophagy.
Main Methods:
- Assessed sensitivity of ovarian cancer cell lines and spheroids to various statins and statin-chemotherapy combinations.
- Investigated the role of HMG-CoA reductase (HMG-CoAR) inhibition and autophagy pathway modulation in statin's effects.
- Evaluated cell death kinetics and autophagy markers (LC3-II, p62, Rab7).
Main Results:
- Statins, except pravastatin, exhibited single-agent activity against ovarian cancer cells in vitro and in spheroids.
- Cytotoxicity was mediated by HMG-CoAR inhibition, confirmed by mevalonate and geranylgeraniol rescue experiments.
- Simvastatin modulated autophagy, causing p62 accumulation and Rab7 loss, suggesting impaired autophagosome trafficking, and LC3-II accumulation, indicating earlier autophagy stimulation.
Conclusions:
- Statins demonstrate potential as ovarian cancer therapeutics, warranting clinical trials with optimized dosing and schedules for continuous HMG-CoAR inhibition.
- Simvastatin's complex interactions with the autophagy pathway may contribute to its observed cytotoxic effects in ovarian cancer cells.
